However, we think that this is unlikely as CRC cell lines with KRAS or BRAF mutations seem to preferentially activate the ERK1/2 pathway and when treated with ERK5 inhibitors, cell proliferation is unaffected [23,24]. Here, MAPK3 is linked to colorectal carcinoma.